Price$1216.24-6.15 (-0.50%)
01:30 PM07:45 PM
News · 26 weeks136-37%
2026-01-112026-07-05
Mix5990d
- Other34(58%)
- Insider13(22%)
- SEC Filings7(12%)
- Earnings3(5%)
- Dividends2(3%)
Latest news
25 items- PRA Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics OpportunityIssued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ:CNXU) opened a new research and development facility at adMare BioInnovations’ M4 Innovation Centre, expanding the home of its CXU™ regenerative tissue platform, a single technology the company is designing to scale across soft-tissue restoration markets spanning aesthetics and body contouring, wound care, and breast reconstruction. RENO, Nev., July 01, 2026 (GLOBE NEWSWIRE) -- Biotech Insider, Medical aesthetics has become one of the most closely watched corners of healthcare, drawing established pharmaceutical and device makers into soft-tissue restoration, contouring, and reconstruction. Against that backdrop,
- PRInnovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland ChinaSAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE:LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios® (abemaciclib) in mainland China: Innovent will be responsible for the importation, marketing, distribution and promotion of Verzenios® (abemaciclib) in mainland China;Lilly will c
- PRLilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapyThe positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Journal of Clinical OncologyBRUIN CLL-313 is the first Phase 3 study to evaluate a non-covalent BTK inhibitor exclusively in patients with treatment-naïve CLL and BRUIN CLL-314 is the first Phase 3 CLL trial to compare non-covalent and covalent BTK inhibitors, as well as the first to compare any BTK inhibitors in the treatment-naïve settingIf granted marketing authorization, this would expand pirtobrutinib's indication as a treatment option for patients with CLL in the European Union across all li
- PRWhat Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight managementA new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines – a daily pill or the number 1 most prescribed injectable – accessible to eligible Medicare Part D patients beginning July 1INDIANAPOLIS, June 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced additional details regarding the Medicare GLP-1 Bridge* program taking effect July 1, 2026. Under the program, Medicare Part D patients may be able to access Foundayo (orforglipron) or Zepbound (tirzepatide) KwikPen for single-patient-use for weight management. The Medicare GLP-1 Bridge program will be the first time eligible Medicare Part D patients will be able to broadly receive coverag
- PRLilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disordersINDIANAPOLIS, June 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage company developing orexin receptor 2 agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders."The orexin system plays a fundamental role in human brain health, governing wakefulness, alertness, and the stability of sleep in ways that, when disrupted, can be profoundly disabling," said Carole Ho, Lilly executive vice president and president, Lilly Neuroscience. "For people living with narcolepsy, that disruption is severe and life-altering.
- SECSEC Form 11-K filed by Eli Lilly and Company11-K - ELI LILLY & Co (0000059478) (Filer)
- PRLilly declares third-quarter 2026 dividendINDIANAPOLIS, June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common stock.The dividend is payable on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries
- PRInternational Regulatory Pathways Have Supported Drug Development Across Biotech and PharmaDENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States. Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes. One example is Eli Lilly (NYSE:LLY), whose oncology therapy Jaypirca adv
- INSIDERDirector Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,401 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,723 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- PRZepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatableIn the national campaign Watch This, O'Neal gets real about living with moderate obstructive sleep apnea (OSA) and the moment he decided to do something about itZepbound® (tirzepatide) is the first and only prescription medicine for moderate-to-severe OSA in adults with obesity and should be used along with a reduced-calorie diet and increased physical activityINDIANAPOLIS, June 10, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that basketball legend and cultural icon Shaquille O'Neal is sharing his personal experience with moderate obstructive sleep apnea (OSA), including candid insight into his diagnosis and treatment journey with Zepbound® (tirzepatide). After year
- PRFDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitisEBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS, June 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a regimen of one maintenance dose every eight weeks of a single injection (250 mg/2 mL) of EBGLYSS (lebrikizumab-lbkz) for subcutaneous use in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis. EBGLYSS is already approved for a once-monthly maintenance dose, with long-term data showing durable disease control. Now, EBGLYSS gives patie
- PRLilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trialsIn ACHIEVE-3, Foundayo 17.2 mg drove 57.1% greater relative reduction in A1C and 73.6% greater relative weight loss compared to oral semaglutide 14 mgIn ACHIEVE-2 and ACHIEVE-5, Foundayo delivered significant improvements in blood sugar and weight, with up to 68.6% and 69.1% of participants reaching an A1C goal of ≤6.5% respectivelyLilly plans to submit Foundayo for type 2 diabetes to the U.S. Food and Drug Administration by the end of the second quarterINDIANAPOLIS, June 8, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from three Phase 3 trials in the ACHIEVE program evaluating Foundayo (orforglipron), a small m
- PRLilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopauseIn ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant weight across all stages of menopause, despite the additional challenge of living with type 2 diabetesAcross studies, women taking Foundayo saw meaningful reductions in their waist circumference, a measure associated with reduced abdominal fat and cardiometabolic riskINDIANAPOLIS, June 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), today announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced signi
- PRLilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsIn TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesityIn addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%)In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1CINDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), tod
- PRLilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to ExplodeDENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the
- PRLilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity carePhase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefine oral incretin therapyNew analyses of the ATTAIN program highlight Foundayo's profile in patient populations central to the future of cardiometabolic care, including women at every stage of menopausePivotal Phase 3 results showed retatrutide, a first-in-class triple receptor agonist, delivered powerful results in obesity, type 2 diabetes and other complicationsINDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide
- PRFoundayo and Zepbound now covered for millions of AmericansCVS Caremark begins covering Foundayo June 1 and resumes Zepbound coverage by October 1 Eligible patients may pay as low as $25 a month for their medicineINDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced an access milestone in obesity care: all three of the nation's largest pharmacy benefit managers (PBMs) will cover Lilly's full obesity medicine portfolio. This significantly expands the number of Americans who can access FDA-approved options through their existing insurance."For too long, effective obesity treatment has been out of reach for the people who need it," said Ilya Yuffa, executive vice president and president of Lilly USA and global cust
- PRLilly to participate in Goldman Sachs 47th Annual Global Healthcare ConferenceINDIANAPOLIS, May 27, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, will take part in a fireside chat at 3:20 p.m. Eastern time.A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We'v
- PRLilly announces three acquisitions to build infectious disease portfolioAgreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or treatAcquisitions build on Lilly's infectious disease legacy and reinforce its commitment to prevention strategies that reduce the long-term burden of serious diseaseINDIANAPOLIS, May 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand its research and development efforts into infectious disease. The transaction
- PRA single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemiaIn the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in participants at high risk for cardiovascular diseaseVERVE-102 is designed to mimic the protective effect of naturally occurring loss-of-function variants in PCSK9, which are associated with markedly lower lifetime risk of coronary heart diseaseLilly plans to begin enrolling the Phase 2 clinical study of VERVE-102 by the end of this yearINDIANAPOLIS, May 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational i
- PRPeptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness MarketsNEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The market for peptide-based health and performance products has been growing fast as more consumers focus on fitness, recovery, longevity, weight management, and overall wellness. Peptides are being widely explored for areas tied to muscle recovery, metabolic health, anti-aging research, and performance optimization. What used to be a niche biotech category is now attracting attention from wellness brands, pharmaceutical companies, and investors looking for exposure to one of the faster-growing areas of healthcare innovation. Those seeking high-growth opportunities in wellness and biotech should watch these c
- PRLilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialIn TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss, a level long associated with bariatric surgery Individuals with a baseline BMI ≥35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks At the 4 mg dose, reached with only a single escalation step, participants lost an average of 47.2 lbs (19.0%) at 80 weeks with a lower observed discontinuation rate due to adverse events vs. placeboINDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide) and Foundayo
LLY FAQ
7 questionsWhat does Eli Lilly and Company do?
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer...Where does LLY stock trade?
Eli Lilly and Company (LLY) is listed on NYSE.What sector and industry is LLY in?
Eli Lilly and Company operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does LLY pay a dividend?
Yes. LLY's next ex-dividend date is 2026-08-14 with a declared cash dividend of $1.73 per share, payable 2026-09-10.What are analysts saying about LLY?
Eli Lilly and Company has had 8 recent analyst actions on file. The most recent action was from HSBC Securities: Reduce on 2026-03-17.What companies are similar to LLY?
Notable peers in the same industry include AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), GSK (GSK plc). Compare LLY side-by-side with any of them on Quantisnow.How can I track LLY on Quantisnow?
Quantisnow aggregates Eli Lilly and Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LLY to receive live email and push alerts on every new disclosure.